Cell culture media for regenerative medicines seen topping $9 billion by 2030

By AI, Created 5:15 PM UTC, May 18, 2026, /AGP/ – The Business Research Company says the global market for cell culture media used in regenerative medicines will surpass $9 billion by 2030, driven by stem cell therapies, chemically defined media and biopharmaceutical manufacturing. North America and the U.S. are projected to lead growth, while liquid media remains the dominant product category.

Why it matters: - The market sits at the center of regenerative medicine production, where media quality affects cell growth, viability and scalability. - The category is projected to reach more than $9 billion by 2030, or about 40% of the broader regenerative medicine market. - Demand is rising as cell and gene therapies move from research into clinical and commercial manufacturing.

What happened: - The Business Research Company released a market report on cell culture media for regenerative medicines. - The report projects the market will grow at a 12% CAGR through 2030. - North America is forecast to be the largest region in 2030, at $3.3 billion. - The U.S. is forecast to be the largest country in 2030, at $3.0 billion. - The liquid media segment is expected to be the biggest product category, with 69% of the market, or about $9 billion, in 2030. - The report also identifies tissue engineering, stem cell research, cell therapy, drug discovery and development, and other applications as key application segments. - Pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic laboratories, and cell banks are listed as key end users.

The details: - North America is expected to grow from $2.0 billion in 2025 to $3.3 billion in 2030, a 11% CAGR. - The U.S. market is expected to rise from $1.8 billion in 2025 to $3.0 billion in 2030, also at an 11% CAGR. - The report ties North American growth to an expanding regenerative medicine pipeline, more stem cell and gene therapy trials, established biomanufacturing infrastructure, more biotech-research partnerships and stronger funding. - The U.S. outlook is linked to a dense biotech base, faster personalized medicine development, more FDA approvals, strong contract manufacturing support and demand for scalable, high-quality media. - Liquid media is favored for large-scale cell expansion, better cell viability and growth, and compatibility with automated bioprocessing systems. - Liquid media demand is also being supported by serum-free and chemically defined formulations. - The report says liquid media will support stem cell and tissue engineering workflows. - Collectively, the liquid, semi-solid and solid media segments are projected to add more than $4 billion by 2030. - Liquid media is projected to grow by $3 billion over the next five years. - Semi-solid and solid media are projected to grow by $1 billion over the same period. - The report says the parent regenerative medicine market is expected to be about $23 billion by 2030. - The broader pharmaceuticals market is expected to reach $2,496 billion by 2030, putting this market at about 0.4% of total industry value. - The Business Research Company says it has published more than 17,500 reports across 27 industries and 60+ geographies, using 1,500,000 datasets plus secondary research and interviews. - The company also offers custom research services, including market entry, competitor tracking, and supplier and distributor packages. - The report includes a free sample request and the full report.

Between the lines: - The fastest-growing opportunities appear to be in media that can support reproducible, contamination-resistant and large-scale manufacturing. - The report points to a broader industry shift toward animal component-free and chemically defined media, which is important for regulatory compliance and batch consistency. - Growth estimates for the main drivers suggest the market is being shaped by both therapy development and manufacturing readiness.

What’s next: - The report expects stem cell and regenerative therapies, chemically defined media and biopharmaceutical manufacturing to keep pushing demand higher through 2030. - More partnerships between industry and academia are likely to support new media formulations and process automation. - Manufacturers are expected to keep investing in scalable media systems for clinical and commercial use.

The bottom line: - Regenerative medicine is turning cell culture media into a scale business, with liquid formulations and North America leading the next phase of growth.